N-Phenylacetyl-L-prolylglycine ethyl ester

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
N-Phenylacetyl-L-prolylglycine ethyl ester
Clinical data
Trade namesNoopept
Other namesN-Phenylacetyl-l-prolylglycine ethyl ester; GVS-111
Legal status
Legal status
  • US: Unscheduled Not FDA approved
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass318.367 g/mol g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

N-Phenylacetyl-l-prolylglycine ethyl ester is promoted as a nootropic and is a prodrug of cycloprolylglycine.[1] Other names include the brand name Noopept (Russian: Ноопепт), developmental code GVS-111; proposed INN omberacetam.[1][2][3]

Its synthesis was first reported in 1996.[1] It is orally available, and as of 2017 its metabolism and elimination half-life were not well understood, as cycloprolylglycine had not been measured in humans following administration.[1]

As of 2017 there had been many studies conducted in cells and in animal models, and there had been one clinical trial with 41 subjects, which compared Noopept and piracetam in people with traumatic brain injury.[1]


  1. ^ a b c d e "Noopept Information". Examine.com. Retrieved 6 April 2017.
  2. ^ "Proposed INN List 117" (PDF). WHO Drug Information. 31 (2): 308. 2017.
  3. ^ "GVS 111". AdisInsight. Retrieved 12 May 2018.